Collegium Pharmaceutical: A Promising Small-Cap Drug Manufacturer with Diversified Portfolio
ByAinvest
Tuesday, Mar 31, 2026 7:37 am ET1min read
COLL--
Collegium Pharmaceutical (COLL) is a small-cap drug manufacturer that has recently acquired Corium Therapeutics Holdings for $650 million in cash and up to $135 million in earn-outs. The acquisition will diversify COLL's topline and contribute to its revenue base through the late 2030s. COLL is also partnering with Boston Legacy FC to make its home games more comfortable and inclusive for fans. The company offers a range of pain management medicines, including Jornay PM, Belbuca, and Nucynta ER.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet